Sohm Stock Price, News & Analysis

SOHM Inc. (SHMN) is described in recent company communications as a pharmaceutical and biotechnology company specializing in generic drugs, gene-editing tools, health and wellness solutions, and biotechnology-driven cosmeceuticals. Although classified under medicinal and botanical manufacturing in the manufacturing sector, SOHM presents itself as a biopharmaceutical business focused on gene editing technologies for research, synthetic biology, and therapeutic applications, while also maintaining a legacy in wellness, skin health, and therapeutic-grade formulations.

According to its public statements, SOHM is dedicated to developing and commercializing gene editing technologies with an emphasis on precision medicine. The company repeatedly highlights a goal of providing safe, efficient, and targeted gene editing solutions and positions its work as contributing to the advancement of gene therapy and genome editing. In parallel, SOHM notes activity in pharmaceuticals, nutraceuticals, topicals, health and wellness solutions, and plans for biotechnology-based cosmeceuticals.

Gene editing and the ABBIE platform

A central element of SOHM's biotechnology focus is its proprietary ABBIE genome-engineering platform. Company materials describe ABBIE as a platform designed to enable DNA insertion events through a programmable enzyme architecture. Earlier iterations used a dCas9-based approach, and later communications describe ABBIE version 2 featuring an advanced dCas12a domain that can modify cultured human cells. SOHM states that ABBIE is intended to support controlled genomic engineering without viral vectors, with preclinical work focused on genomic safety, mechanism, and reproducibility.

SOHM has released a technical white paper on ABBIE as a Cas9-guided integrase platform that enables donor-DNA integration without double-strand breaks or viral vectors. In that work, ABBIE was used to establish SKOV3-GYS1, an ovarian cancer cell line with stable overexpression of glycogen synthase 1 (GYS1) to support drug discovery applications focused on glycogen metabolism. The company reports that this cell line offers an in vitro platform for mechanistic studies and for screening GYS1-targeting small molecules and other metabolic modulators.

In addition, SOHM reports that ABBIE version 2, using a dCas12a domain, has successfully modified cultured human cells and is being advanced toward multi-target editing capabilities through crRNA arrays. The company links this to potential applications in drug discovery and cellular engineering, including the creation of specialized cellular tools such as the ovarian cancer cell line with GYS1 overexpression.

Intellectual property and international patents

SOHM has announced that it received a Notice of Allowance from the South Korea Patent Office for technology titled "CAS9 Retroviral Integrase and CAS9 Recombinase Systems for Targeted Incorporation of a DNA Sequence into a Genome of a Cell or Organism" (Patent Application No. 10-2024-7041475). Company statements describe this patent as part of a growing global intellectual property portfolio around the ABBIE gene-editing platform, which fuses dCas9 with retroviral integrases. Earlier successes in Europe are referenced in the same context, and the company characterizes this IP estate as a foundation for partnerships and for positioning ABBIE as a solution for site-specific integration.

Broader biotechnology and healthcare focus

Across multiple communications, SOHM characterizes itself as a company active in pharmaceuticals, nutraceuticals, topicals, and biotechnology, with a product history emphasizing wellness, skin health, and therapeutic-grade formulations. It also refers to health and wellness solutions and personal health products. The company states that its investment in a dedicated biotech division enables it to pursue biologically inspired skincare technologies and modern bioprocessing platforms.

SOHM has outlined strategic goals to expand into biotechnology-driven cosmeceuticals. It describes planned exploration of biologically sourced actives such as exosomes, peptides, and regenerative proteins, along with cell culture and fermentation methods for producing cosmetic ingredients, and formulation strategies aimed at absorption, stability, and skin bioactivity. These efforts are presented as aligned with the company's broader vision of moving into innovation-focused product categories with emphasis on intellectual property and scientific credibility.

Facilities and operational footprint

SOHM has announced the relocation of its operations to a commercialization facility in Vista, California. The company describes this facility as an industrial building with a mix of office and lab space and warehouse space, intended to support manufacturing, research and development, and biotech commercialization. SOHM links this move to its plans to accelerate growth, support new product launches, and expand its presence in healthcare markets, while enhancing operational efficiency and product development pipelines.

Digital presence and investor-facing materials

SOHM has launched a redesigned corporate website, which it describes as intended to improve navigation and access to information for customers, collaborators, and investors. The company notes that the site presents information on its mission, vision, products and services, and provides materials related to the ABBIE genome editing platform and investor information such as annual reports and shareholder materials. SOHM has also announced plans for an e-commerce website to support a business-to-consumer strategy for cosmeceuticals, nutraceuticals, and over-the-counter products.

Corporate governance and leadership additions

Company announcements describe the appointment of new leadership and advisory personnel. SOHM has reported appointing an independent director with experience in corporate law, mergers and acquisitions, and financial management, and notes that this background is expected to support its governance framework. It has also announced a Vice President of Operations with experience in site operations management, manufacturing, quality control, and supply chain management in regulated industries, with responsibilities that include quality systems and process validation. In addition, SOHM has added an advisory board member with expertise in cosmeceuticals and personal health products, whose background includes work with exosome technologies for skin health and phytoextract-based topical applications.

Strategic positioning and areas of focus

In its own descriptions, SOHM emphasizes several themes: precision medicine, gene editing technologies for research and therapeutic applications, synthetic biology, and gene therapy. It presents the ABBIE platform and associated intellectual property as central to its biotechnology strategy, while also highlighting ongoing involvement in pharmaceuticals, generic drugs, health and wellness solutions, and plans for biotechnology-based cosmeceuticals.

SOHM's communications also reference interest in partnerships and out-licensing related to the ABBIE platform, particularly in connection with multi-target editing capabilities, specialized cellular tools, and drug discovery applications. The company states that it welcomes strategic partnerships to support assay development, screening campaigns, and platform optimization using ABBIE-engineered models.

Stock and market context

SOHM Inc. trades under the symbol SHMN on the OTC market (OTC PINK/OTCID as referenced in company news). Public communications connect the company's activities to broader interest in genome editing and biotechnology, but specific financial metrics, market share, or analyst perspectives are not provided in the available materials.

Key business themes

• Biopharmaceutical and biotechnology focus with specialization in gene editing technologies.
• Development and commercialization of the ABBIE genome-engineering platform, including Cas9-guided integrase and dCas12a-based approaches.
• Activities in pharmaceuticals, generic drugs, nutraceuticals, topicals, health and wellness solutions, and biotechnology-driven cosmeceuticals.
• Emphasis on precision medicine, gene therapy, and synthetic biology applications.
• Investment in intellectual property, including patents related to Cas9 integrase and recombinase systems.
• Operational expansion through a commercialization facility in Vista, California, and enhancements to digital and e-commerce capabilities.